YMAB - Y-mAbs Therapeutics, Inc.

QQQ $ 475.24 $ 0.61 (0.13 %)

DIA $ 406.80 $ 0.86 (0.21 %)

SPY $ 554.24 $ 1.24 (0.22 %)

TLT $ 97.41 $ 0.34 (0.35 %)

GLD $ 231.90 $ 5.08 (2.24 %)

Previous Close

$ 12.24

Open

Bid

$ 12.23 x 200

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 4.69 - $ 20.90

Volume

217,039

Average Volume

Market Cap

538.83M

Beta (5Y Monthly)

$ 1.48

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-29-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-10-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	03-30-2023	12-31-2022	10-K
8	11-07-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	03-12-2020	12-31-2019	10-K
20	11-13-2019	09-30-2019	10-Q
21	08-14-2019	06-30-2019	10-Q
22	05-10-2019	03-31-2019	10-Q
23	03-22-2019	12-31-2018	10-K
24	11-13-2018	09-30-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Initiates Coverage On Y-...
08/16/2024 11:46:02

Cantor Fitzgerald analyst Li Watsek initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Overweight rating and ann...

Canaccord Genuity Maintains Buy on Y-mAbs ...
08/13/2024 16:26:27

Canaccord Genuity analyst Bill Maughan maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $26 price target.

Assessing Y-mAbs Therapeutics: Insights Fr...
08/13/2024 14:01:03

Morgan Stanley Maintains Underweight on Y-...
08/13/2024 12:53:38

Morgan Stanley analyst Michael Ulz maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Underweight and lowers the price targe...

HC Wainwright & Co. Reiterates Buy on Y-mA...
08/13/2024 12:25:59

HC Wainwright & Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $22 price...

BMO Capital Maintains Outperform on Y-mAbs...
08/13/2024 11:36:54

BMO Capital analyst Etzer Darout maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and lowers the price target f...

Y-mAbs' Cash And Cash Equivalents Of $77.8...
08/12/2024 10:34:55

Y-mAbs' Anticipated 2024 Total Net Revenue...
08/12/2024 10:33:47

Anticipated Operating Expenses expected to remain between $115 million and $120 million;Anticipated Total Annual Cash Burn expe...

Y-mAbs Therapeutics Q2 2024 GAAP EPS $(0.2...
08/12/2024 10:31:57

why-ainos-shares-are-trading-higher-by-around-38-here-are-20-stocks-moving-premarket

Why Ainos Shares Are Trading Higher By Aro...
08/12/2024 10:04:36

Jones Trading Initiates Coverage On Y-mAbs...
07/11/2024 20:46:35

Jones Trading analyst Justin Walsh initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and announces P...

msc-industrial-direct-radius-recycling-and-3-stocks-to-watch-heading-into-tuesday

MSC Industrial Direct, Radius Recycling An...
07/02/2024 06:29:42

Y-mAbs Therapeutics Appoints Peter Pfreund...
07/01/2024 20:07:11

Pfreundschuh previously served as Chief Financial Officer at Voyager Therapeutics, Inc.

Truist Securities Initiates Coverage On Y-...
06/28/2024 11:12:54

Truist Securities analyst Nicole Germino initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and annou...

Y-MAbs Therapeutics Says Preclinical GD2-S...
06/07/2024 11:09:22

HC Wainwright & Co. Maintains Buy on Y-mAb...
05/13/2024 17:37:53

HC Wainwright & Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price tar...

Y-mAbs Reiterates Guidance
05/07/2024 21:56:28

2024 Financial GuidanceManagement reiterates its full year 2024 guidance:Anticipated total DANYELZA® net product revenues of be...

Y-mAbs Therapeutics Q1 2024 GAAP EPS $(0.1...
05/07/2024 21:43:33

Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $...

Y-mAbs Therapeutics Announces Resignation ...
03/14/2024 13:06:43

Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical compa...

Cracking The Code: Understanding Analyst R...
03/06/2024 14:00:24